An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

Trial Profile

An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Voxergolide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Registrational
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 19 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top